Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma

Patients will be evaluated for objective response, Duration of Response (DOR), Progression
Free Survival (PFS), Clinical Benefit Rate (CBR), Overall survival (OS), safety and
tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and changes in health related
quality of life. Patients may receive treatment until disease progression, death,
unacceptable toxicity, or withdrawal of consent. An independent data safety monitoring
committee (iDMC) will evaluate the data pertaining to the futility and decide whether the
study should stop or continue to the second stage. If the study continues to the second
stage, a total of 139 patients will be studied.

Inclusion Criteria:

- Is able to understand and voluntarily sign an informed consent document before any
study related assessments/procedures are conducted.

- Has histologically confirmed Grade 1, 2, or 3a follicular lymphoma.

- Has follicular lymphoma that has relapsed after (progressed after 6 months from the
start of therapy) or is refractory to the last line of therapy (no response or
progression within 6 months from the start of therapy) and needs treatment (must have
at least 1 lymph node or extranodal lymphoid malignancy radiologically measuring ≥ 3
cm in its longest diameter).

- Female patients must fulfil the following criteria:

a. Be of non-childbearing potential, defined as follows: i. Postmenopausal (ie, ≥ 1
year without any menses) prior to Screening, or ii. Documented surgically sterile (≥ 1
month prior to Screening)

- Male patients must agree not to donate sperm starting from the time of Screening,
throughout the study, and until after 90 days following the last dose.

- Use highly effective forms of birth control (women of childbearing potential only),
which include the following:

i. Consistent and correct use of established oral contraception ii. Established
intrauterine device or intrauterine system iii. Barrier methods of contraception:
condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal
foam/gel/film/cream/suppository.

- Female patients must agree not to breastfeed starting from the time of Screening,
throughout the study, and until after 90 days following the last dose.

- Male patients and their female spouse/partners who are of childbearing potential must
use highly effective contraception methods consisting of 2 forms of birth control (at
least 1 of which must be a barrier method) from the time of Screening, throughout the
study, and until after 90 days following the last dose.

- Male patients must agree not to donate sperm starting from the time of Screening,
throughout the study, and until after 90 days following the last dose.

Exclusion Criteria:

- Has diagnosis of Grade 3b follicular lymphoma, or transformation to diffuse large
B-cell lymphoma

- Has a history of central nervous system lymphoma (either primary or secondary).

- Has had prior treatment with abexinostat.

- Has had allogeneic stem cell transplant within the last 6 months, or autologous stem
cell transplant within the last 3 months before enrollment

- Has any types of cardiac impairment at the time of enrollment

- Has received any investigational medication within 30 days or 5 half-lives prior to
Day 1, whichever is longer

- Has prior history of malignancies, other than follicular lymphoma, unless the patient
has been free of the disease for ≥ 3 years